Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin

British Journal of Neurosurgery

Volumn 13, Issue 2, 1999, Pages 132-137

  Whittle, I R ^a   Malcolm, G ^b   Jodrell, D I ^b   Reid, M ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Anaplastic astrocytoma; Brain tumour; Carboplatin; Chemotherapy glioblastoma

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; PLATINUM;

ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; CYTOTOXICITY; DISEASE SEVERITY; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; GLIOMA; HISTOLOGY; HUMAN; INTRAOPERATIVE PERIOD; INTRAVENOUS DRUG ADMINISTRATION; MALE; NECROSIS; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARBOPLATIN; FEMALE; GLIOMA; HUMANS; INFUSIONS, INTRAVENOUS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED;

EID: 0032968505     PISSN: 02688697     EISSN: None     Source Type: Journal    
DOI: 10.1080/02688699943871     Document Type: Article

References (23)

1. Dodion P, Sanders C, Georges P, Kenis Y. In vitro chemosensirivity of brain tumours to cisplatin, and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 1988;22:80-2.
2. Doz F, Berens ME, Dougherty DV, et al. Comparison of the cytotoxic activities of cisplatin and carboplatin agaisnt glioma cell lines at pharmacologically relevant drug exposures. J Neurooncol 1991;11:27-35.
3. Lunardi P, Osman Farah J, Mastronardie L, et al. Intravenous administration of high doses of Carboplatin in multimodal treatment of high grade gliomas: a Phase 2 study. Acta Neurochir (Wien) 1996;138:215-20.
4. Poisson M, Pereon Y, Chiras J, et al. Treatment of recurrent malignant supratentorial glioma with Carboplatin (CBDCA). J Neuroomol 1991;10:139-44.
5. Twelves CJ, Ash CM, Miles CW, et al. Activity and toxicity of carboplatin and iproplatin in relapsed high grade glioma. Cancer Chemother Pharmacol 1991; 27:481-3.
6. Warnick RE, Prados MD, Mack EE, et al. A phase 2 study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 1994;19:69-74.
7. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma. A phase 2 study. J Clin Oncol 1991;9:860-4.
8. Cloughesy T, Black KL. Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 1995;26:125-32.
9. Koga H, Inamura T, Ikezaki K, et al. Increased delivery of a new cisplatin analogue (254-S) in rat brain tumour by an intracarotid infusion of bradykinin. Neurol Res 1996;18:244-7.
10. Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of Carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog RMP-7. Neurosurgery 1996;39:125-34.
11. Nomura T, Inamura T, Black KL. Intracarotid infusion of bradykinin selectively increases blodd-turnour permeability in 9L and C6 brain tumours. Brain Res 1994; 659:62-6.
12. Gregor A, Lind M, Osborn C, et al. RMP-7 and carboplatin in recurrent malignant glioma. J Neurooncol 1997;35(Suppl 1):S54.
13. Calvert AH, Newell DR, Grumbell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
15. van der Vijh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991;21:242-61.
16. Unterberg A, Dautermann C, Baethmann A, et al. The kallikrein-kinin system as a mediator of vasogenic brain edema; part 3 inhibition of the kallikrein-kinin system in traumatic brain swelling. J Neurosurg 1986;64: 269-76.
17. Matsukado K, Nakano S, Bartus R, et al. Steroids decrease uptake of carboplatin in rat gliomas- uptake improved by intracarotid infusion of bradykinin analog, RMP-7. J Neurooncol 1997;34:131-8.
18. Malcolm GP, Jodrell D, MacLennan A, Kelly PAT, Swaroop GR, Whittle IR. The effects of nitric oxide modulation on carboplatin disposition in experimental glioma. Neuroreport 1998;9:181-5.
19. G-nitro-L-arginine methyl ester and 3-morpholinosydnonimine upon local cerebral blood flow in an implantation glioma model in rat. Br J Pharmacol 1995;116:274.
20. Whittle IR, Collins F, Kelly PA, et al. Nitric oxide synthasc is expressed in experimental malignant glioma and influences tumour blood flow. Acta Neurochir (Wien) 1996;138:870-6.
21. Shinohara C, Matsumoto K, Kuriyama M, et al. Clinical pharmacokinetics of carboplatin and MCNU in malignant brain tumours and normal brain tissues. J Cancer Chemother 1994;21:1163-8.
22. Donelli MG, Zuchetti M, D'Incalci M. Do anticancer agents reach the tumour target in the human brain. Cancer Chemother Pharmacol 1992;30:251-60.
23. Black KL, Cloughesy T, Huang SC, et al. Intracarotid infusion of RMP-7, a bradykinin analogue and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 1997;86:603-9.